CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients

Publication date: November 2017
Source:Neurobiology of Aging, Volume 59
Author(s): Tobias Skillbäck, Louise Delsing, Jane Synnergren, Niklas Mattsson, Shorena Janelidze, Katarina Nägga, Lena Kilander, Ryan Hicks, Anders Wimo, Bengt Winblad, Oskar Hansson, Kaj Blennow, Maria Eriksdotter, Henrik Zetterberg
A connection between dementias and blood-brain barrier (BBB) dysfunction has been suggested, but previous studies have yielded conflicting results. We examined cerebrospinal fluid (CSF)/serum albumin ratio in a large cohort of patients diagnosed with Alzheimer's disease (AD, early onset [EAD, n = 130], late onset AD [LAD, n = 666]), vascular dementia (VaD, n = 255), mixed AD and VaD (MIX, n = 362), Lewy body dementia (DLB, n = 50), frontotemporal dementia (FTD, n = 56), Parkinson's disease dementia (PDD, n = 23), other dementias (other, n = 48), and dementia not otherwise specified (NOS, n = 271). We compared CSF/serum albumin ratio to 2 healthy control groups (n = 292, n = 20), between dementia diagnoses, and tested biomarker associations. Patients in DLB, LAD, VaD, MIX, other, and NOS groups had higher CSF/serum albumin ratio than controls. CSF/serum albumin ratio correlated with CSF neurofilament light in LAD, MIX, VaD, and other groups but not with AD biomarkers. Our data show that BBB leakage is common in dementias. The lack of association between CSF/serum albumin ratio and AD biomarkers suggests that BBB dysfunction is not inherent to AD but might represent concomitant cerebrovascular pathology.



http://ift.tt/2u7FGAw